Mannisto PT, Garcia-Horsman JA (2017)
Mechanism of Action of Prolyl Oligopeptidase (PREP) in Degenerative Brain Diseases: Has Peptidase Activity Only a Modulatory Role on the Interactions of PREP with Proteins?
Front Aging Neurosci 9: 27

Savolainen MH, Richie CT, Harvey BK, Mannisto PT, Maguire-Zeiss KA, Myohanen TT (2014)
The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse
Neurobiol Dis 68: 1

Tenorio-Laranga J, Peltonen I, Keskitalo S, Duran-Torres G, Natarajan R, Mannisto PT, Nurmi A, Vartiainen N, Airas L, Elovaara I, Garcia-Horsman JA (2013)
Alteration of prolyl oligopeptidase and activated alpha-2-macroglobulin in multiple sclerosis subtypes and in the clinically isolated syndrome
Biochemical Pharmacology 85: 1783

Kaszuba K, Rog T, Danne R, Canning P, Fulop V, Juhasz T, Szeltner Z, St Pierre JF, Garcia-Horsman A, Mannisto PT, Karttunen M, Hokkanen J, Bunker A (2012)
Molecular dynamics, crystallography and mutagenesis studies on the substrate gating mechanism of prolyl oligopeptidase.
Biochimie 94: 1398

Myohanen TT, Hannula MJ, Van Elzen R, Gerard M, Van der Veken P, Garcia-Horsman JA, Baekelandt V, Mannisto PT, Lambeir AM (2012)
A prolyl oligopeptidase inhibitor, KYP-2047, reduces alpha-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease
British Journal of Pharmacology 166: 1097

Myohanen TT, Pyykko E, Mannisto PT, Carpen O (2012)
Distribution of prolyl oligopeptidase in human peripheral tissues and in ovarian and colorectal tumors
Journal of Histochemistry & Cytochemistry 60: 706

Myohanen TT, Tenorio-Laranga J, Jokinen B, Vazquez-Sanchez R, Moreno-Baylach MJ, Garcia-Horsman JA, Mannisto PT (2011)
Prolyl oligopeptidase induces angiogenesis both in vitro and in vivo in a novel regulatory manner
British Journal of Pharmacology 163: 1666

Peltonen I, Mannisto PT (2011)
Effects of diverse psychopharmacological substances on the activity of brain prolyl oligopeptidase
Basic Clin Pharmacol Toxicol 108: 46

Peltonen I, Myohanen TT, Mannisto PT (2011)
Association of prolyl oligopeptidase with conventional neurotransmitters in the brain
CNS Neurol Disord Drug Targets 10: 311

Tenorio-Laranga J, Mannisto PT, Garcia-Horsman JA (2011)
Hunting for peptide substrates of prolyl oligopeptidase: classical versus non-classical bioactive peptides
CNS Neurol Disord Drug Targets 10: 319

Tenorio-Laranga J, Venalainen JI, Mannisto PT, Garcia-Horsman JA (2008)
Characterization of membrane-bound prolyl endopeptidase from brain
Febs J 275: 4415

Garcia-Horsman JA, Mannisto PT, Venalainen JI (2007)
On the role of prolyl oligopeptidase in health and disease
Neuropeptides 41: 1

Garcia-Horsman JA, Venalainen JI, Lohi O, Auriola IS, Korponay-Szabo IR, Kaukinen K, Maki M, Mannisto PT (2007)
Deficient activity of mammalian prolyl oligopeptidase on the immunoactive peptide digestion in coeliac disease
Scand J Gastroenterol 42: 562

Jarho EM, Wallen EA, Christiaans JA, Forsberg MM, Venalainen JI, Mannisto PT, Gynther J, Poso A (2005)
Dicarboxylic acid azacycle l-prolyl-pyrrolidine amides as prolyl oligopeptidase inhibitors and three-dimensional quantitative structure-activity relationship of the enzyme-inhibitor interactions
Journal of Medicinal Chemistry 48: 4772

Venalainen JI, Juvonen RO, Mannisto PT (2004)
Evolutionary relationships of the prolyl oligopeptidase family enzymes
European Journal of Biochemistry 271: 2705

Venalainen JI, Juvonen RO, Forsberg MM, Garcia-Horsman A, Poso A, Wallen EA, Gynther J, Mannisto PT (2002)
Substrate-dependent, non-hyperbolic kinetics of pig brain prolyl oligopeptidase and its tight binding inhibition by JTP-4819
Biochemical Pharmacology 64: 463